Key Considerations When Integrating an End-To-End Single-Use mAbs Production Facility

In an exclusive interview with Miriam Monge, Head of Segment Marketing mAb at Sartorius, Nienke Vriezen, Synthon’s Director of USP Development and Manufacturing, talks about how Sartorius helped Synthon to rapidly implement a flexible single-use facility for the manufacture of monoclonal antibodies. Founded in 1991, Synthon now employs 1,700 people at nine sites worldwide. The company develops biopharmaceuticals with a focus is on next-generation cancer drugs.